Metformin Hydrochloride in Treating Patients With Early-Stage Breast Cancer

2014-08-27 03:14:39 | BioPortfolio


RATIONALE: Metformin hydrochloride may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.

PURPOSE: This randomized phase III trial is studying how well metformin hydrochloride works compared with placebo in treating patients with early-stage breast cancer.




- To compare invasive disease-free survival of patients with early-stage breast cancer treated with metformin hydrochloride vs placebo in addition to standard adjuvant therapy.


- To compare overall survival of these patients.

- To compare distant disease-free survival of these patients.

- To compare breast cancer-free interval in these patients.

- To compare invasive disease-free survival of patients who are hormone receptor-negative (both estrogen receptor and progesterone receptor).

- To compare changes in body mass index in these patients.

- To compare adverse events in these patients.

- To compare other medical endpoints, including a new diagnosis of diabetes mellitus or cardiovascular hospitalization (including an emergency room visit or overnight stay) or death (stroke or myocardial infarction), in these patients.

- To compare health-related quality of life measured using the EORTC QLQ-C30 (supplemented by a trial-specific checklist), the Block Alive Screener, and physical activity items from the Nurses Health Study Questionnaire II on a subset of these patients.

- To compare embedded correlative science outcomes including plasma insulin and molecular markers of metformin hydrochloride action in these patients.

- To compare metabolic parameters including metabolic components of the insulin resistance syndrome as defined by the ATP III criteria in a subset of these patients.

OUTLINE: This is a multicenter study. Patients are stratified according to hormone-receptor status (estrogen receptor- and/or progesterone receptor- positive vs both receptors negative), body mass index (≤ 30 vs > 30 kg/m²), HER2 status (positive vs negative), and prior chemotherapy (any vs none). Patients are randomized to 1 of 2 treatment arms.

- Arm I: Patients receive oral metformin hydrochloride twice daily (once daily in weeks 1-4). Treatment continues for up to 5 years in the absence of disease progression or unacceptable toxicity.

- Arm II: Patients receive oral placebo twice daily (once daily in weeks 1-4). Treatment continues for up to 5 years in the absence of disease progression or unacceptable toxicity.

Blood and tumor samples are collected periodically for correlative studies.

Patients may complete quality-of-life, physical activity, and diet questionnaires at baseline and at 6, 12, 24, 36, 48, and 60 months.

After completion of study treatment, patients are followed annually.

Study Design

Allocation: Randomized, Control: Placebo Control, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment


Breast Cancer


metformin hydrochloride, placebo


Not yet recruiting


NCIC Clinical Trials Group

Results (where available)

View Results


Published on BioPortfolio: 2014-08-27T03:14:39-0400

Clinical Trials [6666 Associated Clinical Trials listed on BioPortfolio]

Metformin Hydrochloride and Doxycycline in Treating Patients With Localized Breast or Uterine Cancer

This phase II trial studies how well metformin hydrochloride works together with doxycycline in treating patients with localized breast or uterine cancer. Metformin hydrochloride may stop ...

Double-blind Comparative Study of SYR-322-MET.

To evaluate the safety and efficacy of treatment with metformin hydrochloride in diabetic patients when used in combination with SYR-322.

Efficacy and Safety of Adjuvant Metformin for Operable Breast Cancer Patients

The investigators hypothesize that adjuvant metformin use in breast cancer patients with overweight or pre-diabetes mellitus (DM) may improve their body condition including weight loss. ...

Phase II Study of Metformin for Reduction of Obesity-Associated Breast Cancer Risk

Overweight and obesity are well established risk factors for breast cancer that develop after menopause. The increased postmenopausal breast cancer risk in women who are overweight or obes...

A Trial of Standard Chemotherapy With Metformin (vs Placebo) in Women With Metastatic Breast Cancer

The purpose of this study is to determine if the addition of metformin to standard chemotherapy improves progression free survival in women with metastatic breast cancer.

PubMed Articles [15277 Associated PubMed Articles listed on BioPortfolio]

The benefits of adding metformin to tamoxifen to protect the endometrium- a randomized placebo-controlled trial.

We investigated whether metformin prevents tamoxifen-induced endometrial changes and insulin resistance (IR) after a diagnosis of breast cancer.

Metformin inhibits human breast cancer cell growth by promoting apoptosis via a ROS-independent pathway involving mitochondrial dysfunction: pivotal role of superoxide dismutase (SOD).

Despite a growing body of evidence indicating a potential efficacy of the anti-diabetic metformin as anti-cancer agent, the exact mechanism underlying this efficacy has remained largely unknown. Here,...

Assessment of Taste and Grittiness of Riomet ER Strawberry, Riomet ER Grape, Riomet Cherry, and Metformin Immediate-Release Tablets in Healthy Subjects.

This study was conducted to evaluate the taste and grittiness of two formulations of Riomet ER (metformin hydrochloride for extended release [ER] oral suspension 100 mg/mL) differing only in their fl...

Metformin exhibited anticancer activity by lowering cellular cholesterol content in breast cancer cells.

Metformin, a widely prescribed anti-diabetic drug, shows anticancer activity in various cancer types. Few studies documented that there was a decreased level of LDL and total cholesterol in blood seru...

Metformin Promotes Antitumor Immunity via Endoplasmic-Reticulum-Associated Degradation of PD-L1.

Metformin has been reported to possess antitumor activity and maintain high cytotoxic T lymphocyte (CTL) immune surveillance. However, the functions and detailed mechanisms of metformin's role in canc...

Medical and Biotech [MESH] Definitions

A pharmaceutical preparation of sitagliptin phosphate and metformin hydrochloride that is used in the treatment of TYPE 2 DIABETES.

Abnormal accumulation of lymph in the arm, shoulder and breast area associated with surgical or radiation breast cancer treatments (e.g., MASTECTOMY).

Metastatic breast cancer characterized by EDEMA and ERYTHEMA of the affected breast due to LYMPHATIC METASTASIS and eventual obstruction of LYMPHATIC VESSELS by the cancer cells.

A infiltrating (invasive) breast cancer, relatively uncommon, accounting for only 5%-10% of breast tumors in most series. It is often an area of ill-defined thickening in the breast, in contrast to the dominant lump characteristic of ductal carcinoma. It is typically composed of small cells in a linear arrangement with a tendency to grow around ducts and lobules. There is likelihood of axillary nodal involvement with metastasis to meningeal and serosal surfaces. (DeVita Jr et al., Cancer: Principles & Practice of Oncology, 3d ed, p1205)

A deoxycytidine derivative and fluorouracil PRODRUG that is used as an ANTINEOPLASTIC ANTIMETABOLITE in the treatment of COLON CANCER; BREAST CANCER and GASTRIC CANCER.

More From BioPortfolio on "Metformin Hydrochloride in Treating Patients With Early-Stage Breast Cancer"

Quick Search


Relevant Topics

Clincial Trials
In a clinical trial or interventional study, participants receive specific interventions according to the research plan or protocol created by the investigators. These interventions may be medical products, such as drugs or devices; procedures; or change...

Women's Health
Women's Health - key topics include breast cancer, pregnancy, menopause, stroke Follow and track Women's Health News on BioPortfolio: Women's Health News RSS Women'...

Searches Linking to this Trial